REFRACTORY ENDOMETRIAL MIXED CELL ADENOCARCINOMA

Clinical trials for REFRACTORY ENDOMETRIAL MIXED CELL ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY ENDOMETRIAL MIXED CELL ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for REFRACTORY ENDOMETRIAL MIXED CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Hormone blockers join forces against Treatment-Resistant endometrial cancer

Disease control Completed

This phase II trial tests whether combining two hormone-blocking drugs — onapristone and anastrozole — can shrink tumors or slow cancer growth in women with hormone-receptor-positive endometrial cancer that has not responded to prior chemotherapy. Onapristone blocks progesterone …

Matched conditions: REFRACTORY ENDOMETRIAL MIXED CELL ADENOCARCINOMA

Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control

Last updated Jul 19, 2026 00:00 UTC

REFRACTORY ENDOMETRIAL MIXED CELL ADENOCARCINOMA

Get alerted when new REFRACTORY ENDOMETRIAL MIXED CELL ADENOCARCINOMA trials appear

Hormone blockers join forces against Treatment-Resistant endometrial cancer